Current research in therapeutic targets
In 2018, the expert opinion on therapeutic target is increased by 4.621 and it is 0.5 increased in the year 2019. Studies have shown that amyloid-β (Aβ) protein deposition is an early event that may be in the development of Alzheimer’s, but the mechanisms that link Aβ to neurodegeneration are poorly understood, so require more research.
The report also states that clinically-relevant symptoms tend to appear at the same time as tau pathology is correlated with cell death, meaning that prevention of the disease is difficult to study.
Furthermore, some parts of the brain such as the hippocampus and amygdala seem to show a selective weakness to plaque accumulation and tau-associated neurodegeneration, while others like the cerebellum are initially spared
- Track 1-1 Encouraging early drug discovery to identify targets
- Track 2-2 Investigating the effects of genetic risk factors on disease
- Track 3-3 Improving understanding of brain nerve cells are more resilient than others
- Track 4-4 Ensuring the right selection for clinical trials
- Track 5-5 Improving ways to measure the efficacy of drugs
- Track 6-6 Finding ways to begin clinical trials decades earlier than is currently conducted.